Grants & Patents 1993- 2017
Alan G. Barbour
1993- 2107
NIH Grants- $122 Million
Patents- 23
With all that money coming in and multiple sources of potential income from patents, test kits, vaccines and vaccine trials, Barbour continues to claim he has no "interests" to declare, no competing interests, or conflicts of interest, or he just won't say. For example...
"There are no patents, products in development or marketed products to declare." Source
"The author has declared that no competing interests exist." Source
"No potential conflicts of interest." Source
"The authors declare that they have no competing interests." Source
"The authors declare that they have no competing interests." Source
"The authors of this letter declare that they have no competing interests." Source
"The authors declare that there are no conflicts of interest." Source
"The author has declared that no competing interests exist." Source
No Claims Statement- This work was supported by grants (AI-088079 to D.F. and P.J.K. and AI-100236 to A.G.B.) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Source
No Claims Statement- The research was supported by National Institutes of Health grant AI-065359 Source
No Claims Statement- The project described was supported by the Preventive Health Services Block Grant from the Centers for Disease Control and Prevention. Laboratory work at University of California Irvine was supported by the National Institutes of Health grant AI-065359. Source
No Claims Statement- This work was supported by grants (AI088079 to D.F. and P.J.K. and AI100236 to A.G.B.) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Source
No Claims Statement- This work was supported by Public Health Service grants AI-24424 and AI-100236 from the National Institute of Allergy and Infectious Diseases. Source
Connected To The IDSA 2006 Guideline Authors- Alan Barbour is also on the Board of Directors of the American Lyme Disease Foundation.
Alan Barbour Quote- "Many consider Lyme disease to be a nuisance that involves a trip to the physician's office every year or two and a few weeks of antibiotics." Alan G. Barbour, MD, Lyme Disease, The Cause, The Cure, The Controversy, page 243. Source
Alan Barbour Quote-“Lyme disease is primarily a disorder of suburban, educated middle- and upper-class people. Lyme disease can be as disabling as syphilis, but there usually is not a stigma to having Borrelia burgdorferi infection.” Alan Barbour, MD. Journal of the American Medical Association, January 21, 1998. Source
Alan Barbour Quote- “Currently, there are many sources of information about Lyme disease, much of which is in disagreement with the experts' advice. These sources include the Internet, books on Lyme disease written by laypersons, and pamphlets, newsletters, and call-in help lines of patient advocacy groups.” Alan Barbour, MD. Journal of the American Medical Association, January 21, 1998. Source
Alan Barbour Quote- "Studies have shown that an infected tick normally cannot begin transmitting the spirochete until it has been attached to its host about 36-48 hours..." Source
Alan Barbour Quote- "The EM rash, which may occur in up to 90% of the reported cases..." Source
Alan Barbour Quote- "The clear distinction of the LD [Lyme Disease] and the RF [relapsing fever] groups of microbes based on numerous highly reliable markers... should aid in the improved diagnosis as well as treatment of these two diseases, which is hindered by the conflation of a common name for agents causing two different types of diseases." Source [It should also help with more grant research funding and more vaccine funding for Barbour.]
NIH Grants
Total In NIH Grants- Over $122 MILLION
LONG, ANTHONY DOUGLAS et al.
UNIVERSITY OF CALIFORNIA-IRVINE
2017
NIAID
NIAID
$154,500
LONG, ANTHONY DOUGLAS et al.
UNIVERSITY OF CALIFORNIA-IRVINE
2016
NIAID
NIAID
$270,375
BORRELIA MIYAMOTOI INFECTION IN MICE AND HUMANS
BOCKENSTEDT, LINDA K et al.
YALE UNIVERSITY
2015
NIAID
NIAID
$670,392
INFORMATIVE IMMUNODIAGNOSTICS FOR LYME DISEASE
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2013
NIAID
NIAID
$192,448
6084
INFECTION AND IMMUNITY IN RESERVOIR HOSTS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2013
NIAID
$131,294
6089
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2013
NIAID
$1,603,094
7344
IDENTIFICATION OF SIGNATURE GASES FOR THE DIAGNOSIS OF INFECTIOUS DISEASES
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2013
NIAID
$431,288
PACIFIC SOUTHWEST RCE FOR BIODEFENSE & EMERGING INFECTIOUS DISEASES RESEARCH
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2013
NIAID
NIAID
$8,653,168
INFORMATIVE IMMUNODIAGNOSTICS FOR LYME DISEASE
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2012
NIAID
NIAID
$230,188
PACIFIC SOUTHWEST RCE FOR BIODEFENSE & EMERGING INFECTIOUS DISEASES RESEARCH
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2012
NIAID
NIAID
$11,075
6084
INFECTION AND IMMUNITY IN RESERVOIR HOSTS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2012
NIAID
$224,275
6089
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2012
NIAID
$1,381,767
7344
IDENTIFICATION OF SIGNATURE GASES FOR THE DIAGNOSIS OF INFECTIOUS DISEASES
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2012
NIAID
$303,864
PACIFIC SOUTHWEST RCE FOR BIODEFENSE & EMERGING INFECTIOUS DISEASES RESEARCH
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2012
NIAID
NIAID
$9,206,084
6084
INFECTION AND IMMUNITY IN RESERVOIR HOSTS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2011
NIAID
$170,569
6089
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2011
NIAID
$779,728
PACIFIC SOUTHWEST RCE FOR BIODEFENSE & EMERGING INFECTIOUS DISEASES RESEARCH
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2011
NIAID
NIAID
$8,985,358
PACIFIC SOUTHWEST RCE FOR BIODEFENSE & EMERGING INFECTIOUS DISEASES RESEARCH
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2010
NIAID
NIAID
$146,092
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2010
NIAID
NIAID
$344,719
6084
INFECTION AND IMMUNITY IN RESERVOIR HOSTS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2010
NIAID
$159,440
6089
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2010
NIAID
$562,705
PACIFIC SOUTHWEST RCE FOR BIODEFENSE & EMERGING INFECTIOUS DISEASES RESEARCH
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2010
NIAID
NIAID
$8,627,554
6084
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2009
NIAID
$162,208
6089
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2009
NIAID
$711,951
PACIFIC SOUTHWEST RCE FOR BIODEFENSE & EMERGING INFECTIOUS DISEASES RESEARCH
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2009
NIAID
NIAID
$9,625,099
PACIFIC SOUTHWEST RCE FOR BIODEFENSE & EMERGING INFECTIOUS DISEASES RESEARCH
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2009
NIAID
NIAID
$3,853,630
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2009
NIAID
NIAID
$349,653
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2008
NIAID
NIAID
$350,963
9008
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2008
NIAID
$1,621,895
PACIFIC-SOUTHWEST CTR FOR BIODEFENSE & EMERG INFECT DIS*
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA-IRVINE
2008
NIAID
NIAID
$10,078,421
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2007
NIAID
NIAID
$358,965
9008
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2007
NIAID
$1,573,950
PACIFIC-SOUTHWEST CTR FOR BIODEFENSE & EMERG INFECT DIS*
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2007
NIAID
NIAID
$9,805,034
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2006
NIAID
NIAID
$370,808
9008
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2006
NIAID
$1,334,149
PACIFIC-SOUTHWEST CTR FOR BIODEFENSE & EMERG INFECT DIS*
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2006
NIAID
NIAID
$9,796,830
8309
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2005
NIAID
$934,739
9008
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2005
NIAID
$1,683,840
PACIFIC-SOUTHWEST CTR FOR BIODEFENSE & EMERG INFECT DIS*
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2005
NIAID
NIAID
$9,980,000
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2005
NIAID
NIAID
$351,183
BIOLOGY AND CONTROL OF LYME DISEASE BORRELIA
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2004
NIAID
NIAID
$291,879
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2004
NIAID
NIAID
$351,906
BIOLOGY AND CONTROL OF LYME DISEASE BORRELIA
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2003
NIAID
NIAID
$291,879
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2003
NIAID
NIAID
$352,608
BIOLOGY AND CONTROL OF LYME DISEASE BORRELIA
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2002
NIAID
NIAID
$291,879
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2002
NIAID
NIAID
$353,289
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2001
NIAID
NIAID
$348,223
BIOLOGY AND CONTROL OF LYME DISEASE BORRELIA
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2001
NIAID
NIAID
$291,879
BIOLOGY AND CONTROL OF LYME DISEASE BORRELIA
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2000
NIAID
NIAID
$304,479
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
2000
NIAID
NIAID
$339,003
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
1999
NIAID
NIAID
$326,031
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
1998
NIAID
NIAID
$313,556
INTERFACE OF BORRELIA SURFACE PROTEINS AND ANTIBODIES
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
1998
NIAID
NIAID
$274,422
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
1997
NIAID
NIAID
$301,563
INTERFACE OF BORRELIA SURFACE PROTEINS AND ANTIBODIES
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
1997
NIAID
NIAID
$263,869
GORDON CONFERENCE--BIOLOGY OF THE SPIROCHETES
BARBOUR, ALAN G.
GORDON RESEARCH CONFERENCES
1996
NIAID
NIAID
$2,000
NIAMS
$2,000
NIDCR
$2,000
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
1996
NIAID
NIAID
$42,084
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
1996
NIAID
NIAID
$247,498
INTERFACE OF BORRELIA SURFACE PROTEINS AND ANTIBODIES
BARBOUR, ALAN G.
UNIVERSITY OF CALIFORNIA IRVINE
1996
NIAID
NIAID
$253,721
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
1995
NIAID
NIAID
$268,054
INTERFACE OF BORRELIA SURFACE PROTEINS AND ANTIBODIES
BARBOUR, ALAN G.
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
1995
NIAID
NIAID
$235,988
INTERFACE OF BORRELIA SURFACE PROTEINS AND ANTIBODIES
BARBOUR, ALAN G.
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
1994
NIAID
NIAID
$180,481
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
1994
NIAID
NIAID
$257,746
GENETIC AND PATHOGENICITY OF BORRELIA BURGDORFERI
BARBOUR, ALAN G.
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
1994
NIAID
NIAID
$183,884
MOLECULAR BASIS OF BORRELIA PATHOGENESIS
BARBOUR, ALAN G.
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
1993
NIAID
NIAID
$257,742
GENETIC AND PATHOGENICITY OF BORRELIA BURGDORFERI
BARBOUR, ALAN G.
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
1993
NIAID
NIAID
$183,350
Source- https://projectreporter.nih.gov/reporter_SearchResults.cfm?icde=34980872
Additional Funding By Various Private Organizations
Total Amounts Of Grants- Unknown
Example of Grantor- Bay Area Lyme Foundation
Patents- 23
Show/Hide Search CriteriaThere were 23 connections of patents to projects matching your search criteria.
Click on the column header to sort the results
Core NIH Project NumberPatent NumberPatent TitlePatent Owner Primary Agency
U54AI065359
8597941
Bioreactor for quantification of headspace VOC content from cultures
UNIVERSITY OF CALIFORNIA SYS OFFICE/PRES
U54AI065359
9637748
Conjugative plasmids and methods of use thereof
UNIVERSITY OF WISCONSIN-MADISON
R01AI024424
6617441
Diagnostic test for borrelia infection
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
R37AI024424
6617441
Diagnostic test for borrelia infection
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
R01AI024424
5932220
Diagnostic tests for a new spirochete, Borrelia lonestari sp. nov.
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
R37AI024424
5932220
Diagnostic tests for a new spirochete, Borrelia lonestari sp. nov.
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
R37AI024424
5436000
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
R01AI024424
6077515
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
R37AI024424
6077515
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
R01AI024424
5436000
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
R01AI024424
5585102
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
R37AI024424
5585102
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
U54AI065359
8093064
Method for using magnetic particles in droplet microfluidics
UNIVERSITY OF CALIFORNIA LOS ANGELES
U54AI065359
9279808
Method of detecting and identifying circulating antigens in human biological samples
UNIVERSITY OF NEVADA RENO
U54AI065359
8962237
Method of detecting and identifying circulating antigens in human biological samples
UNIVERSITY OF NEVADA RENO
U54AI065359
9310365
Method of diagnosing and treating melioidosis
UNIVERSITY OF NEVADA RENO
U54AI065359
8753831
Methods for detection of botulinum neurotoxin
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
U54AI065359
8067192
Methods for detection of botulinum neurotoxin
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
U54AI065359
8435759
Plasmid-encoded neurotoxin genes in Clostridium botulinum serotype A subtypes
UNIVERSITY OF WISCONSIN-MADISON
U54AI065359
9453057
Plasmid-encoded neurotoxin genes in Clostridium botulinum serotype A subtypes
UNIVERSITY OF WISCONSIN-MADISON
U54AI065359
8263104
NORTHWESTERN UNIVERSITY
U54AI065359
9498521
Purification, characterization, and use of Clostridium botulinum neurotoxin BoNT/A3
UNIVERSITY OF WISCONSIN-MADISON
U54AI065359
8440204
Subtype of Closteridium botulinum neurotoxin type A and uses thereof
UNIVERSITY OF WISCONSIN-MADISON
Source- https://projectreporter.nih.gov/reporter_PatResults.cfm?icde=34980872
PubMed Search Results
Terms- Barbour, Borrelia, Vaccine
36 Abstracts
1989- 2015
Cook V, Barbour AG.
Ticks Tick Borne Dis. 2015 Jul;6(5):549-58. doi: 10.1016/j.ttbdis.2015.04.009. Epub 2015 Apr 28.
PMID:
26005106
Select item 246957752.
Diversity of antibody responses to Borrelia burgdorferi in experimentally infected beagle dogs.
Baum E, Grosenbaugh DA, Barbour AG.
Clin Vaccine Immunol. 2014 Jun;21(6):838-46. doi: 10.1128/CVI.00018-14. Epub 2014 Apr 2.
PMID:
24695775
Select item 238263013.
Baum E, Randall AZ, Zeller M, Barbour AG.
PLoS One. 2013 Jun 24;8(6):e67445. doi: 10.1371/journal.pone.0067445. Print 2013.
PMID:
23826301
Select item 187707914.
Detection of borreliacidal antibodies by flow cytometry.
Callister SM, Jobe DA, Schell RF.
Curr Protoc Cytom. 2004 Nov;Chapter 11:Unit 11.5. doi: 10.1002/0471142956.cy1105s26.
PMID:
18770791
Select item 165843335.
Ornstein K, Barbour AG.
Vector Borne Zoonotic Dis. 2006 Spring;6(1):103-12.
PMID:
16584333
Select item 156080696.
Tsao JI, Wootton JT, Bunikis J, Luna MG, Fish D, Barbour AG.
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18159-64. Epub 2004 Dec 17.
PMID:
15608069
Select item 129198557.
Sen E, Schell RF.
Microbes Infect. 2003 Aug;5(10):869-78.
PMID:
12919855
Select item 126531378.
Tsao J, Barbour AG, Luke CJ, Fikrig E, Fish D.
Vector Borne Zoonotic Dis. 2001 Spring;1(1):65-74.
PMID:
12653137
Select item 126154429.
Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM.
Vaccine. 2003 Mar 28;21(13-14):1455-65.
PMID:
12615442
Select item 1206901610.
Ornstein K, Berglund J, Bergström S, Norrby R, Barbour AG.
Scand J Infect Dis. 2002;34(5):341-6.
PMID:
12069016
Select item 1198230411.
Laboratory testing for suspected Lyme disease.
Bunikis J, Barbour AG.
Med Clin North Am. 2002 Mar;86(2):311-40. Review.
PMID:
11982304
Select item 1130912112.
Bunikis J, Mirian H, Bunikiene E, Barbour AG.
Mol Microbiol. 2001 Apr;40(2):387-96.
PMID:
11309121
Select item 1099837413.
Antigenic variation in vector-borne pathogens.
Barbour AG, Restrepo BI.
Emerg Infect Dis. 2000 Sep-Oct;6(5):449-57. Review.
PMID:
10998374
Select item 1072053214.
Luke CJ, Marshall MA, Zahradnik JM, Bybel M, Menefee BE, Barbour AG.
J Infect Dis. 2000 Mar;181(3):1062-8.
PMID:
10720532
Select item 1067942315.
Borrelia pathogenesis research in the post-genomic and post-vaccine era.
Nordstrand A, Barbour AG, Bergström S.
Curr Opin Microbiol. 2000 Feb;3(1):86-92. Review.
PMID:
10679423
Select item 1041172216.
Sohaskey CD, Zückert WR, Barbour AG.
Mol Microbiol. 1999 Jul;33(1):41-51.
PMID:
10411722
Select item 1033849417.
Bunikis J, Barbour AG.
Infect Immun. 1999 Jun;67(6):2874-83.
PMID:
10338494
Select item 1006769718.
Edelman R, Palmer K, Russ KG, Secrest HP, Becker JA, Bodison SA, Perry JG, Sills AR, Barbour AG, Luke CJ, Hanson MS, Stover CK, Burlein JE, Bansal GP, Connor EM, Koenig S.
Vaccine. 1999 Feb 26;17(7-8):904-14.
PMID:
10067697
Select item 935293719.
Analysis of promoters in Borrelia burgdorferi by use of a transiently expressed reporter gene.
Sohaskey CD, Arnold C, Barbour AG.
J Bacteriol. 1997 Nov;179(21):6837-42.
PMID:
9352937
Select item 917847620.
Luke CJ, Huebner RC, Kasmiersky V, Barbour AG.
Vaccine. 1997 Apr-May;15(6-7):739-46.
PMID:
9178476
Select item 898520121.
An OspA-based DNA vaccine protects mice against infection with Borreliaburgdorferi.
Luke CJ, Carner K, Liang X, Barbour AG.
J Infect Dis. 1997 Jan;175(1):91-7.
PMID:
8985201
Select item 897340222.
Unusual strain of Borrelia burgdorferi isolated from Ixodes dentatus in central Georgia.
Oliver JH Jr, Chandler FW Jr, James AM, Huey LO, Vogel GN, Sanders FH Jr.
J Parasitol. 1996 Dec;82(6):936-40.
PMID:
8973402
Select item 899335823.
Sadziene A, Thompson PA, Barbour AG.
Ann N Y Acad Sci. 1996 Oct 25;797:140-50. No abstract available.
PMID:
8993358
Select item 862707124.
Sadziene A, Thompson PA, Barbour AG.
J Infect Dis. 1996 May;173(5):1184-93.
PMID:
8627071
Select item 874012225.
Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview.
Sadziene A, Barbour AG.
Infection. 1996 Mar-Apr;24(2):195-202. Review.
PMID:
8740122
Select item 789042426.
Borrelia burgdorferi mutant lacking Osp: biological and immunological characterization.
Sadziene A, Thomas DD, Barbour AG.
Infect Immun. 1995 Apr;63(4):1573-80.
PMID:
7890424
Select item 789039427.
McGrath BC, Dunn JJ, Gorgone G, Guttman D, Dykhuizen D, Luft BJ.
Infect Immun. 1995 Apr;63(4):1356-61. Erratum in: Infect Immun 1995 Jun;63(6):2390.
PMID:
7890394
Select item 761066428.
Sadziene A, Barbour AG.
Wien Med Wochenschr. 1995;145(7-8):162-5. Review. German.
PMID:
7610664
Select item 831537829.
Stover CK, Bansal GP, Hanson MS, Burlein JE, Palaszynski SR, Young JF, Koenig S, Young DB, Sadziene A, Barbour AG.
J Exp Med. 1993 Jul 1;178(1):197-209.
PMID:
8315378
Select item 850300630.
The biological and social phenomenon of Lyme disease.
Barbour AG, Fish D.
Science. 1993 Jun 11;260(5114):1610-6. Review.
PMID:
8503006
Select item 841806831.
Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA.
Erdile LF, Brandt MA, Warakomski DJ, Westrack GJ, Sadziene A, Barbour AG, Mays JP.
Infect Immun. 1993 Jan;61(1):81-90.
PMID:
8418068
Select item 147551932.
Antigenic variation and strain heterogeneity in Borrelia spp.
Wilske B, Barbour AG, Bergström S, Burman N, Restrepo BI, Rosa PA, Schwan T, Soutschek E, Wallich R.
Res Microbiol. 1992 Jul-Aug;143(6):583-96. Review.
PMID:
1475519
Select item 155474133.
France LL, Kieleczawa J, Dunn JJ, Hind G, Sutherland JC.
Biochim Biophys Acta. 1992 Mar 27;1120(1):59-68.
PMID:
1554741
Select item 205613334.
Sadziene A, Thomas DD, Bundoc VG, Holt SC, Barbour AG.
J Clin Invest. 1991 Jul;88(1):82-92.
PMID:
2056133
Select item 213623735.
Dunn JJ, Lade BN, Barbour AG.
Protein Expr Purif. 1990 Nov;1(2):159-68.
PMID:
2136237
Select item 276138836.
Bergström S, Bundoc VG, Barbour AG.
Mol Microbiol. 1989 Apr;3(4):479-86.
PMID:
2761388
Most Recent NIH Grantor- 2017
NIH - National Institutes of Health
John Salzman
Assistant Extramural Inventions Policy Officer / IT Policy Analyst
NIH Division of Extramural Inventions & Technology Resources (DEITR)
Office of Policy for Extramural Research Administration (OPERA)
Office of Extramural Research (OER), National Institutes of Health
6705 Rockledge Drive, Suite 310, MSC 7980
Bethesda, MD 20892 , US
Phone : (301) 435-1986
Fax : (301) 480-0272
Examples Of Patents
Diagnostic test for borrelia infection
[Also For Future Use In Vaccines]
United States Patent
6,617,441
Barbour , et al.
September 9, 2003
Vaccines for Protection Against B. lonestari sp. nov. Infection
The present inventors contemplate vaccines for use in both active and passive immunization embodiments. Immunogenic compositions, proposed to be suitable for use as a vaccine, may be prepared most readily directly from immunogenic B. lonestari sp. nov.-specific surface antigens, such as Vmp or Osp lipoprotein.
Source
United States Patent
5,585,102
Barbour , et al.
December 17, 1996
**Please see images for: ( Certificate of Correction ) **
Flagella-less borrelia
Abstract
This invention relates to flagella-less strains of Borrelia to novel methods for use of the microorganisms as vaccines and in diagnostic assays. Although a preferred embodiment of the invention is directed to Borrelia burgdorferi, the present invention encompasses flagella-less strains of other microorganisms belonging to the genus Borrelia. Accordingly, with the aid of the disclosure, flagella-less mutants of other Borrelia species, e.g., B. coriacei, which causes epidemic bovine abortion, B. anserina, which causes avian spirochetosis, and B. recurrentis and other Borrelia species causative of relapsing fever, such as Borrelia hermsii, Borrelia turicatae, Borrelia duttoni, Borrelia persica, and Borrelia hispanica, can be prepared and used in accordance with the present invention and are within the scope of the invention. Therefore, a preferred embodiment comprises a composition of matter comprising a substantially pure preparation of a strain of a flagella-less microorganism belonging to the genus Borrelia.